AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05010590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romosozumab
Description: Monthly romosozumab
Study NCT05010590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Every 6 months denosumab
Study NCT06297148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-management
Description: Patients will have 3-5 sessions with a physiotherapist that include individually tailored education, and address physical, cognitive, and behavioral factors deemed as relevant according to the participant's concerns and challenges. Important aspects in this are: problem-solving, decision-making, resource utilization, therapeutic alliance and taking action (The 5 core skills of self-management). SMART goals and an activity plan between sessions will be used as an exposure to maintain, change, or create health behavior.~Participants will have access to study material, including exercise alternatives and a podcast.
Study NCT06297148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care at the department consists of general information about the condition and advice on pain management and exercise. For further treatment, patients are referred to primary care. Participation in the study will not affect how this is conducted.
Study NCT05658354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive program
Description: BrainHQ was developed by Posit Science and includes computer-based brain-training exercises organized into six categories: Attention, Brain Speed, Memory, People Skills, Intelligence, and Navigation. Participants were instructed to perform a total of 24 sessions of computerized cognitive training at home, consisting of 45 minutes of training, twice per week, over a 3-month period.
Study NCT05060731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral iron supplementation
Description: Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.
Study NCT05060731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous iron supplementation
Description: One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
Study NCT01556152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRC 17536 (Medium Dose)
Description: 1 BD for 28 days
Study NCT01556152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRC 17536 (Low Dose)
Description: 1 BD for 28 Days
Study NCT01556152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for 28 Days
Study NCT04975893 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: mRNA-1647
Description: No investigational product will be administered during the Primary Extension Phase or to the participants in the Observational Group.
Study NCT04975893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration
Study NCT05414864 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramelteon (RozeremR)
Description: 8mg daily
Study NCT05414864 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: sleep hygiene
Description: sleep behavioral guidelines
Study NCT06526221 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine isoniazid testing (IsoScreen test)
Description: Developed by Arkansas' Public Health Service in the 1970s, this test detects metabolites of isoniazid, a drug present in drug-susceptible TB regimens. IsoScreen (GFC Diagnostics, UK) is a commercial version of the Arkansas method with reagents enclosed in a plastic vial, into which 2mL of urine can be injected with a syringe. If the urine contains isoniazid, reagents turn purple/blue (suggesting a dose was taken in the last 24 hours or appropriate adherence) or green (suggesting a dose was taken 24-48 hours before or one missed dose). A yellow result (no color change) suggests medication has not been taken for >48 hours (two or more missed doses).
Study NCT05511948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBI-102
Description: Topical application on dorsal hand and upper volar arm
Study NCT05511948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Inactive comparator
Study NCT05511948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone Cream
Description: 4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
Study NCT05253040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KEEP Intervention
Description: Educational intervention
Study NCT05253040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: booklet from Parkinson's UK
Study NCT06544460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary cytoreduction
Description: Repeated tumor cell reduction surgery for recurrent ovarian cancer patients
Study NCT06544460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy
Description: Using the BR-TQR-I intraperitoneal hyperthermic perfusion chemotherapy instrument, after the surgical operation is completed, four drainage tubes are placed in the left and right upper abdomen and lower abdomen respectively. Connect all pipelines and preheat the instrument before starting treatment. The treatment temperature is controlled at 43 ℃± 0.1 ℃, the treatment time is 90 minutes, and the circulation pump flow rate is 400-600ml/min. Within 48 hours after the surgery, cisplatin 75mg/㎡ was added to 3000ml of physiological saline for intraperitoneal hot infusion. Through the comprehensive effects of circulation flushing, hyperthermia, chemotherapy, and thermochemotherapy sensitization, it kills and removes residual cancer cells or small lesions in the abdominal cavity.
Study NCT06546527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-137
Description: \[177Lu\]Lu-PSMA-137 500 MBq;50% optimal dosing;100% optimal dosing
Study NCT05858814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC1012 injection (allo-DNT cells)
Description: RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
Study NCT05901428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is a deoxyribonucleic acid (DNA) synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
Study NCT05901428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
Study NCT05901428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
Study NCT05025267 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical Food: Peptide-Based Enteral Formula
Description: Will be fed exclusively the study peptide-based, high protein enteral formula via a feeding tube
Study NCT05636852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Altropane (123I) Injection
Description: Each subject will receive a single IV administration of 5 mCi (185 MBq) Altropane.
Study NCT05209412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lepu Paclitaxel coated balloon
Description: Paclitaxel is the pharmacologically active substance for anti-neointima. The active drug coating is located on the surface of the balloon, which contains 1.5 μg Paclitaxel per 1 mm2.
Study NCT05209412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity Zotarolimus eluting stents
Description: The device consists of a balloon-expandable intracoronary drug-eluting stent pre-mounted on the MicroTrac Rapid Exchange stent delivery system. Drug eluting stent is composed of metal stent, primer and drug coating. The Stent is manufactured from a cobalt alloy (MP35N). The strut thickness is 88.9 μm and the length elements is 0.9 mm. The drug coating consists of the zotarolimus and BioLinx polymer (C10/C19/PVP) system. A coating of polymers loaded with zotarolimus in a formulation applied to the entire surface of the stent at a dose of approximately 1.6 µg/mm2 which results in a maximum nominal drug content of 380 µg on the largest stent (4.0 x 38 mm).
Study NCT05209412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.
Study NCT05209412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.
Study NCT05209412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.
Study NCT05209412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.
Study NCT05209412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.
Study NCT05209412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.
Study NCT05393817 — intervention group
Intervention type: DRUG
Intervention: caffeine citrate
Description: caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)
Study NCT05850052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional direct laryngoscopy using a Macintosh blade
Description: Examine a patient's airway to aid placement of tracheal tube with ease.
Study NCT05850052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope for rapid sequence endotracheal intubation
Description: Visualize a patient's airway to aid placement of tracheal tube with ease.
Study NCT05993598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy
Description: Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.
Study NCT04825015 — intervention group
Intervention type: DEVICE
Intervention: VEnaRt Cardiac Output
Description: Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter
Study NCT05332834 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SM17
Description: Peripheral intravenous injection
Study NCT05332834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Peripheral intravenous injection
Study NCT04616053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPACT intervention
Description: A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist ...). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology ...) and/or collective care (for example : patient education, physical activity, relaxation ...). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
Study NCT04846595 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: self questionnaire
Description: Evaluate the demographic variables and medical characteristics of people living with HIV in the Alpine Arc region
Study NCT06291233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Interview Training (VIT)
Description: Teachers will administer the intervention (Virtual Interview Training) with the student participants. University of Michigan research staff will train all teachers (including sites in California) and will provide support as necessary throughout the intervention delivery process. Surveys will be captures several times throughout delivery as delivery is expected to be anywhere between 4 to 6 weeks long.
Study NCT06291233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services-as-usual
Description: Participants will receive services-as-usual at participants school or program for approximately 6 weeks. Those that are in the active control group will receive access to the e-learning content of the Rita/Travis intervention (not the practice interviews) and will be able to review the e-learning content with teacher's supervision. In addition, this group will review a series of video conversations with autistic adults about navigating the pathway to a career. Surveys will be collected at different time points after randomization.
Study NCT05575869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (online) PRONEtect educational material
Description: This is a website containing educational material like short simulation videos on how to turn a patient from supine-to-prone and prone-to-supine positioning, how to protect the skin from incontinence, or before securing endotracheal-/nasogastric tubes, how to reposition the patient to prevent pressure injuries, a full protocol regarding prone positioning etc.
Study NCT05575869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic (normal) one hour lesson/lecture
Description: As per normal, a classroom lecture given by the nursing school by one of the nursing school lecturers.
Study NCT05719038 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: observational study
Description: observational study
Study NCT06611592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.088mg/tid
Description: Week 1 - Week 16 (end of treatment): Oral administration of 0.088 mg/tid dose of pramipexole (0.125 mg of salt).
Study NCT06611592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.18 mg/tid
Description: Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2 -Week 16 (end of treatment): oral administration of 0.18 mg/tid dose of pramipexole (0.25 mg salt).
Study NCT05775250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: giomer varnish
Description: Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
Study NCT05775250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: giomer varnish
Description: Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
Study NCT04991233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Description: The endoscopic surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
Study NCT04991233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital craniotomy surgery
Description: The suboccipital craniotomy surgery will be conducted to evacuate the hemorrhage within 24 hours after SCH.
Study NCT06254105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HANDY programme
Description: The manualised HANDY program includes descriptions of procedures related to the GP's evaluation of the client's need for referral to occupational therapy, procedures for referral from the GP to community-based occupational therapy, the group-based occupational therapy programme, and recommendations related to collaboration and communication between GP and occupational therapist.
Study NCT04719065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
Description: Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.
Study NCT06611592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.35 mg/tid
Description: Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2: oral administration of a 0.18 mg/tid dose of pramipexole (0.25 mg salt).~Week 3 - Week 16 (end of treatment): oral administration of a 0.35 mg/tid dose of pramipexole (0.50 mg salt).
Study NCT06617130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Corn soy bean blended flour porridge plus indispensable amino acid
Description: Protocol treatment will start within two weeks of enrollment to the study. Following the baseline study assessments, each participant will receive corn-soy bean blended flour porridge supplemented with IAAs (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) dosed at 12g/d and providing 1.5 times the estimated average requirement (EAR) for a healthy child (Intervention group). The porridge will provide 30% daily energy requirement. The study foods will be taken once daily by the child with at least three observed feeding sessions per week over the 4 weeks of the study to assess compliance.~Children in the control arm will receive corn-soy blended flour porridge without added amino acids.
Study NCT06617130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn soy bean blended flour porridge plus indispensable amino acid
Description: Protocol treatment will start within two weeks of enrollment to the study. Following the baseline study assessments, each participant will receive corn-soy bean blended flour porridge supplemented with IAAs (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) dosed at 12g/d and providing 1.5 times the estimated average requirement (EAR) for a healthy child (Intervention group). The porridge will provide 30% daily energy requirement. The study foods will be taken once daily by the child with at least three observed feeding sessions per week over the 4 weeks of the study to assess compliance.~Children in the control arm will receive corn-soy blended flour porridge without added amino acids.
Study NCT06616909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP GAME
Description: ,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents
Study NCT06616909 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: acp manual
Description: acp manual
Study NCT06616922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD03/2016 eye drops
Description: 1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.
Study NCT06616922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 0.5% eye drops solution (Oftaquix®)
Description: 1 drop, 8 times a day (approximately every 2 hours while awake) on Days 1 and 2, and 1 drop, 4 times a day (approximately every 4 hours while awake) on Days 3 through 5.
Study NCT06616480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BenQ Materials DSFNC1 soft hydrophilic contact lenses
Description: Test lenses were to be worn for approximately 90 days.
Study NCT06616480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visco SiHy Color soft hydrophilic contact lenses
Description: Control lenses were to be worn for approximately 90 days
Study NCT04901078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNX100
Description: KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
Study NCT04901078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KNX100
Description: KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
Study NCT06502652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy
Description: A hippotherapy simulator is a horse riding simulator exercise machine, mimicking a horse's gait and recreating the horseback riding experience within the safety of a therapy clinic. Child with down syndrome will be seated on the stimulator for 10-15 minutes every session. The patient's pelvis moves softly, rhythmically, and repetitively when riding this action is comparable to what the human pelvis does when walking normally